Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Un essai de phase 3 pour évaluer le CYB003 dans le trouble dépressif majeur (EMBRACE)

30 octobre 2026 mis à jour par: Cybin IRL Limited

Une efficacité et une sécurité, phase III, étude contrôlée multicentrique, en double aveugle et randomisée comparant 2 doses actives de CYB003 et de placebo chez les participants éligibles avec un trouble dépressif majeur

The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD.

For more information about the EMBRACE study, including participating study locations, and to register your interest in learning more about participation, please visit the study website: https://embrace-mdd-trial.com/

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Estimé)

330

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

      • Berlin, Allemagne, 10117
        • Pas encore de recrutement
        • Charité Universitaetsmedizin Berlin
        • Chercheur principal:
          • Michael Koslowski
        • Contact:
      • Frankfurt am Main, Allemagne, 60528
        • Pas encore de recrutement
        • University Hospital Frankfurt
        • Chercheur principal:
          • Andreas Reif
        • Contact:
      • Mannheim, Allemagne, 68159
        • Pas encore de recrutement
        • Central Institute of Mental Health
        • Contact:
        • Chercheur principal:
          • Gerhard Grüender
    • Saarland
      • Homburg, Saarland, Allemagne, 66421
        • Pas encore de recrutement
        • Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes
        • Chercheur principal:
          • Matthias Riemenschneider
        • Contact:
        • Contact:
    • New South Wales
      • Camperdown, New South Wales, Australie, 2050
        • Recrutement
        • Royal Prince Alfred Hospital
        • Chercheur principal:
          • Nicholas Glozier
    • Queensland
      • Maroochydore, Queensland, Australie, 4558
        • Recrutement
        • Thompson Brain & Mind Healthcare (TBMH)
        • Chercheur principal:
          • Adem Can
        • Contact:
        • Contact:
    • Victoria
      • Melbourne, Victoria, Australie, 3004
      • Melbourne, Victoria, Australie, 3053
        • Recrutement
        • Neurocentrix Research
        • Chercheur principal:
          • David Barton
        • Contact:
        • Contact:
      • Notting Hill, Victoria, Australie, 3168
        • Recrutement
        • Monash University - Notting Hill
        • Contact:
        • Chercheur principal:
          • Paul Liknaitzky
      • Athens, Grèce, 12462
        • Recrutement
        • Attikon University Hospital
        • Chercheur principal:
          • Nikolaos Smyrnis
        • Contact:
      • Athens, Grèce, 11528
        • Recrutement
        • Eginitio Hospital
        • Chercheur principal:
          • Nikos Stefanis
        • Contact:
      • Thessaloniki, Grèce, 56404
        • Recrutement
        • Papageorgiou General Hospital
        • Chercheur principal:
          • Georgios Papazisis
        • Contact:
      • Dublin, Irlande, D24 WK80
        • Recrutement
        • Sheaf House - Tallaght Adult Mental Health Service
        • Chercheur principal:
          • John Kelly
        • Contact:
      • Galway, Irlande, H91 VE03
        • Recrutement
        • La Nua Day Hospital Mental Health Centre
        • Contact:
        • Chercheur principal:
          • Shane McInerney
      • Bialystok, Pologne, 15-272
        • Retiré
        • Uniwersytecki Szpital Kliniczny W Białymstoku
      • Bydgoszcz, Pologne, 85-133
        • Recrutement
        • Promente - Centrum Neurologii i Psychogeriatrii w Bydgoszczy
        • Contact:
        • Chercheur principal:
          • Katarzyna Lachut
      • Gdansk, Pologne, 80-546
        • Recrutement
        • Centrum Badan Klinicznych PI-House Sp. z o.o
        • Contact:
        • Chercheur principal:
          • Hanna Badzio-Jagiello
      • Gdansk, Pologne, 80-214
        • Pas encore de recrutement
        • UCK
        • Chercheur principal:
          • Wieslaw Jerzy Cubala
        • Contact:
      • Warsaw, Pologne, 02-957
        • Pas encore de recrutement
        • Department of Pharmacology and Physiology of CNS
        • Chercheur principal:
          • Justyna Holka-Pokorska
      • Warsaw, Pologne, 02-172
        • Recrutement
        • MTZ Clinical Research Powered by Pratia
        • Chercheur principal:
          • Monika Gawlowicz
      • Cambridge, Royaume-Uni, CB1 2EU
        • Recrutement
        • Cambridge University Hospital NHS
        • Chercheur principal:
          • Liliana Galindo
        • Contact:
        • Contact:
      • Doncaster, Royaume-Uni, DN4 8QN
        • Recrutement
        • Clerkenwell Health - Doncaster
        • Chercheur principal:
          • Paul Morrison
        • Contact:
      • Edinburgh, Royaume-Uni, EH16 4TJ
        • Pas encore de recrutement
        • NHS Research Scotland
        • Chercheur principal:
          • Donald MacIntyre
        • Contact:
      • Glasgow, Royaume-Uni, G51 4TF
      • Liverpool, Royaume-Uni, L7 8XP
        • Pas encore de recrutement
        • Royal Liverpool Hospital
        • Contact:
        • Chercheur principal:
          • Fabian Devlin
      • London, Royaume-Uni, EC2Y 8EA
        • Recrutement
        • St Pancras Clinical Research
        • Chercheur principal:
          • Martin Johnson
        • Contact:
      • London, Royaume-Uni, W1U 6RP
      • London, Royaume-Uni, W1G9 RU
        • Recrutement
        • Re:Cognition Health
        • Chercheur principal:
          • Dimitrios Paschos
        • Contact:
          • Numéro de téléphone: +44-0800-802-1030
      • London, Royaume-Uni, SE5 9RS
      • London, Royaume-Uni, W1G 8DR
        • Retiré
        • Clerkenwell Health - Welbeck Street
      • Newcastle upon Tyne, Royaume-Uni, NE4 5PL
      • Reading, Royaume-Uni, RG7 8PA
        • Recrutement
        • Ascend Clinical Research
        • Chercheur principal:
          • Pamela Walters
        • Contact:
      • Sheffield, Royaume-Uni, S4 7QQ
      • Prague, Tchéquie
        • Pas encore de recrutement
        • Institute of neuropsychiatric Care (INEP)
        • Chercheur principal:
          • Alexander Nawka
        • Contact:
          • Numéro de téléphone: +420 222 201 020
          • E-mail: info@inep.cz
      • Prague, Tchéquie
        • Pas encore de recrutement
        • Psyon s.r.o.
        • Chercheur principal:
          • Tomas Palenicek
        • Contact:
      • Předměstí, Tchéquie
        • Pas encore de recrutement
        • A-SHINE s.r.o.
        • Chercheur principal:
          • Lubos Janu
        • Contact:
    • Alabama
      • Birmingham, Alabama, États-Unis, 35209
        • Recrutement
        • UAB Psychiatry and Behavioral Neurology
        • Contact:
        • Chercheur principal:
          • Peter Hendricks
        • Contact:
    • Arizona
      • Gilbert, Arizona, États-Unis, 85234
        • Recrutement
        • Lighthouse Psychiatry
        • Contact:
        • Chercheur principal:
          • Frank Genova
    • Arkansas
      • Little Rock, Arkansas, États-Unis, 72204
        • Retiré
        • Pillar Clinical Research - Little Rock
    • California
      • Glendale, California, États-Unis, 91206
        • Recrutement
        • Behavioral Research Specialists, LLC
        • Chercheur principal:
          • Jesse Carr
        • Contact:
      • Imperial, California, États-Unis, 92251
        • Retiré
        • Sun Valley Research Center
      • Los Angeles, California, États-Unis, 90025
        • Recrutement
        • CalNeuro Research Group
        • Chercheur principal:
          • Alexander Bystritsky
        • Contact:
      • Los Angeles, California, États-Unis, 90025
        • Recrutement
        • Lipov Medical Group
        • Contact:
        • Chercheur principal:
          • Jacob Moussai
      • Orange, California, États-Unis, 92868
        • Recrutement
        • NRC Research Institute
        • Contact:
        • Chercheur principal:
          • Daniel Chueh
      • Orange, California, États-Unis, 92866
        • Recrutement
        • ATP Clinical Research
        • Chercheur principal:
          • Gustavo Alva
        • Contact:
      • San Juan Capistrano, California, États-Unis, 92675
        • Pas encore de recrutement
        • Inland Psychiatric Medical Group Inc (IPMG Research)
        • Chercheur principal:
          • Neelima Kunam
        • Contact:
      • Santa Monica, California, États-Unis, 90404
        • Recrutement
        • Psychedelic Science Institute
        • Chercheur principal:
          • Keith Heinzerling
        • Contact:
      • Stanford, California, États-Unis, 94305
        • Retiré
        • Stanford University
    • Connecticut
      • New Haven, Connecticut, États-Unis, 06511
        • Recrutement
        • Yale School of Medicine - Yale Program for Psychedelic Science
        • Chercheur principal:
          • Ben Kelmendi
        • Contact:
          • Daidre Chamberlain
          • Numéro de téléphone: 203-693-1591
          • E-mail: enact@yale.edu
        • Contact:
    • Florida
      • Jacksonville, Florida, États-Unis, 32256
        • Recrutement
        • CNS Healthcare
        • Contact:
          • Numéro de téléphone: 904-281-5757
        • Chercheur principal:
          • John Mark Joyce
      • Maitland, Florida, États-Unis, 32751
        • Recrutement
        • Accel Research Sites - Maitland
        • Contact:
          • Numéro de téléphone: 407-644-1165
        • Chercheur principal:
          • Andrea Marrafino
      • Naples, Florida, États-Unis, 34105
        • Recrutement
        • Aqualane Clinical Research
        • Chercheur principal:
          • Matthew Baker
        • Contact:
      • Tampa, Florida, États-Unis, 33634
        • Recrutement
        • K2 Medical Research Tampa
        • Chercheur principal:
          • Kelley Wilson
        • Contact:
    • Georgia
      • Atlanta, Georgia, États-Unis, 30329
        • Retiré
        • Emory University Dept of Psychiatry and Behavioral Studies
      • Marietta, Georgia, États-Unis, 30060
        • Recrutement
        • Psych Atlanta
        • Chercheur principal:
          • Michael Banov
        • Contact:
    • Illinois
      • Chicago, Illinois, États-Unis, 60612
        • Recrutement
        • Rush University
        • Chercheur principal:
          • Joshua Eloge
        • Contact:
    • Louisiana
      • Marrero, Louisiana, États-Unis, 70006
        • Retiré
        • Tandem Clinical Research
      • New Orleans, Louisiana, États-Unis, 70115
        • Recrutement
        • Atlas Psychiatry
        • Contact:
        • Chercheur principal:
          • Nicholas Pejic
    • Maryland
      • Baltimore, Maryland, États-Unis, 21224
        • Retiré
        • Johns Hopkins Medicine
      • Rockville, Maryland, États-Unis, 20850
    • Massachusetts
      • Boston, Massachusetts, États-Unis, 02116
        • Recrutement
        • Adams Clinical Boston
        • Chercheur principal:
          • Darin Dougherty
        • Contact:
      • Watertown, Massachusetts, États-Unis, 02472
        • Recrutement
        • Adams Clinical Watertown
        • Chercheur principal:
          • Stephanie Ellickson
        • Contact:
    • Minnesota
      • Eden Prairie, Minnesota, États-Unis, 55347
        • Recrutement
        • Institute for Integrative Therapies
        • Chercheur principal:
          • Manoj Doss
        • Contact:
      • Golden Valley, Minnesota, États-Unis, 55427
        • Pas encore de recrutement
        • The Remedy Mental Health
        • Contact:
        • Chercheur principal:
          • Wayne Bentham
    • Nevada
      • Las Vegas, Nevada, États-Unis, 89119
        • Recrutement
        • Redbird Research, LLC
        • Chercheur principal:
          • Jelena Kunovac
        • Contact:
    • New Jersey
      • Toms River, New Jersey, États-Unis, 08755
        • Recrutement
        • Bio Behavioral Health
        • Contact:
        • Chercheur principal:
          • Ashok Patel
    • New York
      • New York, New York, États-Unis, 10032
        • Pas encore de recrutement
        • New York State Psychiatric Institute
        • Chercheur principal:
          • Natalie Gukasyan
        • Contact:
      • New York, New York, États-Unis, 10029
        • Recrutement
        • Adams Clinical Harlem
        • Chercheur principal:
          • Rachel Noone
        • Contact:
      • The Bronx, New York, États-Unis, 10461
        • Recrutement
        • Adams Clinical Bronx
        • Chercheur principal:
          • Shama Farooq
        • Contact:
    • Oklahoma
      • Oklahoma City, Oklahoma, États-Unis, 73112
        • Retiré
        • SP Research PLLC
    • Pennsylvania
      • Philadelphia, Pennsylvania, États-Unis, 19104
        • Recrutement
        • Adams Clinical Philadelphia
        • Chercheur principal:
          • Cassie Blanchard
        • Contact:
      • Philadelphia, Pennsylvania, États-Unis, 19462
        • Recrutement
        • Flourish Research Philadelphia
        • Chercheur principal:
          • Rachna Saralkar
        • Contact:
          • Numéro de téléphone: 215-614-5606
    • Texas
      • Austin, Texas, États-Unis, 78737
        • Retiré
        • Austin Clinical Trial Partners
      • DeSoto, Texas, États-Unis, 75115
        • Recrutement
        • Adams Clinical Dallas
        • Chercheur principal:
          • Rajinder Shiwach
        • Contact:
      • Fort Worth, Texas, États-Unis, 76104
        • Retiré
        • North Texas Clinical Trials
      • Houston, Texas, États-Unis, 77046
        • Recrutement
        • Brain Health Consultants and TMS Center
        • Chercheur principal:
          • Lauren Marangell
        • Contact:
      • San Antonio, Texas, États-Unis, 78229
    • Washington
      • Everett, Washington, États-Unis, 98201
        • Pas encore de recrutement
        • Core Clinical Research
        • Contact:
        • Chercheur principal:
          • James Knutson
      • Seattle, Washington, États-Unis, 98104
        • Recrutement
        • Seattle Neuropsychiatric Treatment Center
        • Chercheur principal:
          • Rebecca Allen
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 85 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

Participants must meet all the following criteria to be included in the trial:

  • Age18 to 85 years.
  • Participant has a diagnosis of MDD (single or recurrent episode as defined by DSM-5 TR [if single episode, duration of ≥4 weeks and ≤24 months] and established as per evaluation by the Investigator. The first MDD episode must have occurred prior to age 60.
  • Moderate to severe depression at Screening and Baseline, independently confirmed.
  • Participants have been on a stable dose of antidepressant medication (label specified) at an adequate dose in the last 4 weeks prior to Screening and has had an inadequate response (less than 50% improvement), as judged by the Investigator.
  • Participant has a body mass index (BMI) of 40 kg/m2 or less (BMI ≤40 kg/m2), inclusive, at Screening.
  • Participant is able to refrain from nicotine use during the dosing session (up to 8 hours).
  • Participants capable of producing sperm must use a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication, if their partner is a person of childbearing potential.
  • Participants of childbearing potential who have a partner capable of producing sperm must agree to use a highly effective method of contraception in combination with the use of a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication. Such participants must have a negative pregnancy test at Screening and Day 1 prior to dosing.
  • Participants of non-childbearing potential who are or were capable of producing eggs (ova) must have been postmenopausal or permanently sterile following hysterectomy, bilateral salpingectomy, or bilateral oophorectomy.
  • Participants have provided written informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form.

Exclusion Criteria

Participants with any of the following characteristics/conditions will be excluded from trial participation:

  • Current or previously diagnosed schizophrenia spectrum or other psychotic disorders, including schizophrenia, schizoaffective disorder, schizotypal disorder, schizophreniform disorder, brief psychotic disorder, current or previous history of bipolar disorder, or current borderline personality disorder.
  • Participants with a medical diagnosis of attention deficit hyperactivity disorder (ADHD) will be excluded if currently taking medication for ADHD.
  • Family history of schizophrenia, schizoaffective disorder, or bipolar disorder type 1 (first-degree relatives).
  • Significant suicide risk within the past 6 months, during the Screening Period, or at Baseline; or (b) suicidal behaviors within 12 months of Screening; or (c) clinical assessment of significant suicidal risk during clinical interview; or (d) non-suicidal self-injury within 12 months of Screening.
  • Current or previous diagnosis of treatment-resistant MDD, defined as failure to respond to 2 or more antidepressant treatments of 2 different classes given at an adequate dose (label specified) for an adequate duration as judged by the Investigator and clinical interview.
  • Has had electroconvulsive treatment, transcranial magnetic stimulation, deep brain stimulation, or vagal nerve stimulation for any episode of MDD in the last 6 months.
  • Currently receiving a monoamine oxidase inhibitor, tricyclic antidepressants, mirtazapine, trazodone, moclobemide, buspirone, or an antipsychotic or mood stabilizer. Note: if receiving these medications are for another indication, they must be discontinued ≥ 14 days or 5 half-lives, whichever is longer, prior to Day 1.
  • Participant report of (or if available in medical record) exposure to psilocin, or 5-HT2a receptor agonists, or any other psychedelics, such as ayahuasca, mescaline, lysergic acid diethylamide, peyote, or 3,4-methylenedioxymethamphetamine, more than 10 times over the participant's lifetime or any psychedelic use within 12 months prior to Screening.
  • Participant report of (or if available in medical record) treatment with ketamine or S-ketamine use within 6 months prior to Screening.
  • Clinically relevant history of abnormal physical health interfering with the trial (including but not limited to, neurological, cardiovascular, respiratory, gastrointestinal [including dyspepsia or gastroesophageal reflux disease], hepatic, or renal disorder).
  • Has hypothyroidism or hyperthyroidism, unless controlled on appropriate medication.
  • Current diagnosis of uncontrolled hypertension or an arrhythmia, or clinically relevant abnormal results for heart rate.
  • Participants have a presence or relevant history of organic brain disorders.
  • Participant is taking or has taken OTC doses of 5-HTP or St John's Wort within prior to trial medication administration.
  • Donation of blood or plasma within 4 weeks prior to first dosing and until 4 weeks after final dosing.
  • Participants capable of producing sperm who will not abstain from sperm donation between first dosing and 12 weeks after final dosing.
  • Participants of childbearing potential who are pregnant, breastfeeding, planning to conceive or unwilling to abstain from egg (ova) donation between first dosing and 12 weeks after final dosing.
  • History of serotonin syndrome.
  • Unwilling to consent to audio and video recording of psychological support and dosing sessions.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Quadruple

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Experimental Arm A CYB003 in 2 of 2 Dosing Sessions

Arm A participants will receive 8 mg of CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. All Arm A participants will continue on their current antidepressants and receive psychological support throughout the study.

CYB003 is a deuterated psilocin analog.

Manualized psychological support performed by facilitator.

Expérimental: Experimental Arm B CYB003 in 2 of 2 Dosing Sessions

Experimental Arm B participants will receive 16 mg of CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. All Arm B participants will continue on their current antidepressants and receive psychological support throughout the study.

CYB003 is a deuterated psilocin analog.

Manualized psychological support performed by facilitator.

Comparateur placebo: Placebo Comparator: Arm C Placebo in 2 of 2 Dosing Session

Participants will receive placebo in 2 of 2 medicine sessions, approximately three weeks apart. All Arm C participants will continue on their current antidepressants and receive psychological support throughout the study. Non-responders will be eligible to receive CYB003 in a subsequent extension trial.

Manualized psychological support performed by facilitator.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Montgomery-Asberg Depression Scale (MADRS)
Délai: Screening Day-45, Baseline, Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.

The MADRS is a 10-item scale with ratings based on a clinical interview which moves from broadly phased questions about symptoms to more detailed ones allowing a precise rating of severity.

The total score ranges 0-60, higher scores denote greater severity.

Screening Day-45, Baseline, Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
The Beck Depression Inventory - Second Edition (BDI-II)
Délai: Day -1, Day 21, Day 42 and Day 84/End of Trial.

The Beck Depression Inventory-Second Edition (BDI-II) is a 21-question multiple-choice self-report inventory, assessing depressive symptoms and severity.

Each question is scored on a scale value of 0 to 3, with higher total scores indicating more severe depressive symptoms. Each of the 21 items corresponding to a symptom of depression is summed to give a single score for the BDI-II, so the total score possible is 63 and minimum if everything is zero would be 0.

Day -1, Day 21, Day 42 and Day 84/End of Trial.
The Clinical Global Impression Scale (CGI-S)
Délai: Screening Day-45, Baseline Day -1, Day 42, Day 84/End of Trial.

The Clinical Global Impression Scale is a clinician-rated instrument comprised of 3 global measures: severity of illness, global improvement and efficacy index.

Only the severity of illness ang global improvement measures will be utilized for this trial.

Higher score means more severe symptomology, worse outcome. CGI-S scoring is as follows:

  1. = Normal, not at all ill
  2. = Borderline ill
  3. = Mildly ill
  4. = Moderately ill
  5. = Markedly ill
  6. = Severely ill
  7. = Among the most extremely ill patients
Screening Day-45, Baseline Day -1, Day 42, Day 84/End of Trial.
The Generalized Anxiety Disorder 7-Item Scale (GAD-7)
Délai: Baseline Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.

The Generalized Anxiety Disorder 7-Item Scale (GAD-7) is a 7-item self reported assessment that measures the severity of generalized anxiety disorder symptoms.

Participants respond to each item using a 4-point scale from 0 to 3. Participants choose one of 4 severity scores associated with problems related to the common anxiety disorders to indicate the degree to which these problems caused functional and/or social difficulties. A total score is obtained by the sum of all total column values, higher scores indicate more functional/social impairment/difficulties. Score range is as follows:

Scores represent:

0 - 4 = Minimal anxiety 5 - 9 = Mild anxiety 10 - 14 = Moderately anxiety 15 - 21 = Severe anxiety

Baseline Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.
The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)
Délai: Day -1, Day 21, Day 42 and Day 84/End of Trial.

The original Quality of Life Enjoyment and Satisfaction Questionnaire is a 93 item, participant facing, self reported measure used to evaluate intervention-related changes in quality of life, divided int the following sections: physical health, feelings, work, household duties, school, leisure time activities, social relations and general activities.

The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) version will be used in this trial.

Each item rated on a 5-point scale ranging from 1 (very poor) to 5 (very good), higher score indicates greater satisfaction. The scoring of the Q-LES-Q-SF involves summing only the first 14 items to yield a raw total score. The last two items are not included in the total score but are standalone items. The raw total score ranges from 14 to 70. So the minimum raw score on the Q-LES-Q-SF is 14, and the maximum score is 70

Day -1, Day 21, Day 42 and Day 84/End of Trial.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Collaborateurs

Les enquêteurs

  • Directeur d'études: Felix Mazer, Cybin IRL Limited

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

10 décembre 2025

Achèvement primaire (Estimé)

7 juin 2027

Achèvement de l'étude (Estimé)

9 août 2027

Dates d'inscription aux études

Première soumission

21 janvier 2025

Première soumission répondant aux critères de contrôle qualité

21 janvier 2025

Première publication (Réel)

27 janvier 2025

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

2 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

30 octobre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner